SPDR S&P Biotech ETF (NYSEARCA:XBI) is built around a deceptively simple idea: give every biotech company roughly equal footing, regardless of size. That equal-weight structure separates it from ...
Sarepta Therapeutics remains highly volatile as ELEVIDYS sales drive sentiment, with Q4 revenue missing expectations and safety concerns lingering. Despite fading ELEVIDYS sales, SRPT management ...
Hosted on MSN
Why is SRPT stock falling today?
・Sarepta is set to exchange 1.25% convertible senior notes due 2027 for new 4.875% convertible senior notes due 2030, alongside about $31.6 million in cash. ・The transaction is slated to be completed ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The original version of this story appeared in Quanta Magazine. If you want to solve a tricky problem, it often helps to get organized. You might, for example, break the problem into pieces and tackle ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Hosted on MSN
Barclays Downgrades Sarepta Therapeutics (SRPT)
Fintel reports that on July 27, 2025, Barclays downgraded their outlook for Sarepta Therapeutics (NasdaqGS:SRPT) from Equal-Weight to Underweight. Analyst Price Forecast Suggests 214.11% Upside As of ...
We recently published 12 Stocks Jim Cramer Discussed As Analyzed Morgan Stanley’s Comments. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is one of the stocks Jim Cramer recently discussed. Sarepta ...
Sarepta Therapeutics stock (NASDAQ: SRPT) experienced a significant turnaround on Wednesday, with shares rising 33% in after-hours trading following the announcement of an extensive restructuring plan ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results